HOME >> BIOLOGY >> NEWS
Life expectancy following diagnosis of Alzheimers disease depends on age at diagnosis

The life span of people with Alzheimer's disease depends greatly on the age of the person when Alzheimer's disease is diagnosed, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health. Determining the survival following a diagnosis of Alzheimer's disease is important information for helping patients, families, and their caregivers, deal with the illness. The findings are published in the November 18, 2002, edition of Archives of Neurology.

"The duration of survival following a diagnosis of Alzheimer's disease depends critically on the subject's age at diagnosis. The results of this study indicate that the median survival of patients with Alzheimer's disease could range from nearly 9 years for persons diagnosed at age 65 to approximately 3 years for persons diagnosed at age 90 years," said Ronald Brookmeyer, PhD, professor of biostatistics at the Johns Hopkins Bloomberg School of Public Health.

Data for the study was collected from the Baltimore Longitudinal Study of Aging, which began in 1958 to monitor the effects of aging. The participants were asked to return for follow-up visits every two years to be examined and to answer questionnaires. From this study, Dr. Brookmeyer and his colleagues selected 921 participants who were age 55 or older in 1985 and had received some follow-up visits. Alzheimer's disease was diagnosed using several neuropsychological tests and deaths were recorded through September 1999.

The statistical analysis found that the median survival times ranged from 8.3 years for people diagnosed at age 65 to 3.4 years for people diagnosed at age 90. Persons diagnosed with Alzheimer's disease at age 65 could anticipate a 67 percent reduction in life span compared to those without Alzheimer's disease, while persons diagnosed at age 90 could anticipate a 39 percent reduction in life span. The researchers say Alzheimer's disease is associated with a greater proportionate reduction of life span
'"/>

Contact: Tim Parsons
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
18-Nov-2002


Page: 1 2

Related biology news :

1. Common variation of klotho gene associated with human life expectancy
2. Phase II trials of second-generation antisense cancer drug planned following successful early study
3. Putting GPS to work, researchers shed light on road-following by pigeons
4. Tamoxifen stimulates breast cancer growth following alteration of estrogen receptor
5. Leave land alone following natural disasters, say researchers
6. Complement inhibitor decreases heart attacks and death in men following cardiac surgery
7. Researchers learn certain enzyme inhibitors may help in cancer therapy following initial procedures
8. Gene more than doubles risk of depression following life stresses
9. Dyslexic children`s brains operate more like those of normal readers following training
10. A new study sheds light on how the tongue restores its ability to taste following surgery
11. Hopkins researchers find postoperative fevers common following hemispherectomy

Post Your Comments:
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... 2015  With the increasing number and severity of ... concern. The recent compromise of Federal employee data ... authentication within government agencies. HYPR Corp. announced ... (OTP) authenticator, has been submitted for testing and approval ... validation for tamper proofing. The proliferation ...
(Date:6/15/2015)... 16, 2015 According to a ... Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, ... published by MarketsandMarkets, The Natural Language Processing Market is ... of 18.4% for the forecast period 2015-2020. ... F igures spread   through 155 P ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
(Date:7/2/2015)... ... 02, 2015 , ... Sleepless nights will become obsolete as Luzi , ... Indiegogo campaign on June 23. Sound sleepers and the sleep deprived both will love ... use, while the integration of the Bluetooth speaker, alarm clock and ability to charge ...
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
(Date:7/1/2015)... July 1, 2015  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that the ... 22 at 5:45 p.m. EDT following its presentation ... International Conference 2015 (AAIC). The ... , Dr. Lawrence Friedhoff , Chief Development ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company CEO, ... PA. , The presentation took place on Tuesday, June 16 and provided ... development of APX3330 for the treatment of pancreatic cancer. A copy of the ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2
Cached News: